Introduction: Rare cancers are defined as those with an incidence of fewer than 6 cases per 100,000 inhabitants. Factors such as low population frequency and the heterogeneity of these neoplasms pose significant challenges to early diagnosis, robust clinical trials, and the development of targeted therapies. Therefore, it is essential to understand and monitor the epidemiological profile of these conditions.Objectives: To characterize reported cases of rare cancers in the State of Pará from 2014 to 2019. Methods: This is a descriptive, observational, and retrospective study with a quantitative approach, based on the analysis of secondary data from the Population-Based Cancer Registry (RCBP), maintained by the Brazilian National Cancer Institute (INCA). Confirmed cases of rare malignant neoplasms, as classified by INCA and reported between 2014 and 2019, were included. These comprised meningiomas, grade III squamous intraepithelial neoplasias, seminomas, infiltrating ductal carcinomas, malignant teratomas, Burkitt lymphoma, Ewing sarcoma, basal cell carcinoma, and mucinous and sebaceous adenocarcinomas. The variables analyzed were sex, age, tumor topography, and morphology. Descriptive analyses (frequencies, means, and standard deviations) were conducted, along with the calculation of incidence per 100,000 inhabitants, based on the average population during the study period. As this study uses public, secondary, and non-identifiable data, it is exempt from ethical review under Resolution CNS n° 510/2016. Results: From 2014 to 2019, 25,865 cancer cases were reported in Pará, of which 127 (0.49%) were classified as rare cancers. Based on the average population during this period, the estimated incidence was 1.53 cases per 100,000 inhabitants. Notably, INCA’s database does not include data beyond 2019, which may require updates on the current status of rare cancer diagnoses in the state. Most cases occurred in males (55%; 70/127), with females accounting for 45% (57/127). The average age at diagnosis was 46.4 (±20.5) years for males and 35.3 (±21.5) years for females. This age difference may reflect earlier detection in women, particularly for breast, cervical, and ovarian cancers, which together accounted for 31% of cases. The lack of complete data on patients’ educational attainment limits understanding of their health literacy and hinders the development of targeted educational strategies. Regarding histological classification, squamous cell carcinomas (20%), seminomas (16.5%), and infiltrating ductal carcinomas (15.2%) were most prevalent, indicating a predominance of gynecologic and testicular tumors. Squamous cell carcinomas originate from epithelial tissues, commonly affecting the cervix; seminomas are testicular germ cell tumors; and infiltrating ductal carcinomas begin in the mammary ducts, invading surrounding tissues. Conclusion: The characterization of rare cancers in Pará from 2014 to 2019 revealed a low incidence, higher occurrence in males, and predominance of squamous cell, seminoma, and ductal carcinoma subtypes. The absence of key sociodemographic variables highlights the need to improve data reporting. Understanding the regional epidemiological profile may support strategies for earlier diagnosis.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
